AXSM financial statements
The full income statement, balance sheet, and cash-flow statement for Axsome Therapeutics Inc. (AXSM), plus valuation ratios — straight from SEC filings. Switch between annual, quarterly, and trailing-twelve-month figures, pick how far back to look, and flip the time order. Every line has a trend sparkline.
Shares outstanding (point-in-time)
SEC-filed end-of-period counts (cover pages and balance sheets, split-adjusted) — the series realized buyback yield is computed from. The weighted-average share lines in the statements below lag these by design: an average over the year sits near the midpoint of an ongoing buyback.
| Line item | Trend | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Income Statement | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| Revenue | 638M YoY+65.5% | 386M YoY+42.5% | 271M YoY+440.8% | 50.0M | — | |
| Cost of revenue | — | — | — | 5.20M | — | |
— | — | — | — | 125M YoY+25.8% | ||
| Operating income | -167M YoY+40.6% | -281M YoY-21.0% | -232M YoY-28.9% | -180M YoY-44.2% | -125M YoY-25.8% | |
| Interest expense | -15.9M YoY+26.2% | -21.6M YoY-7.7% | -20.0M YoY-107.4% | -9.66M | — | |
| Interest & investment income | 9.37M YoY-37.6% | 15.0M YoY+10.5% | 13.6M YoY+484.4% | 2.32M | — | |
| Pre-tax income | -184M YoY+36.0% | -287M YoY-20.5% | -238M YoY-27.3% | -187M YoY-43.5% | -130M | |
| Income tax | -530K YoY-723.5% | 85.0K YoY-91.1% | 960K | 0.00 | 0.00 | |
| Net income | -183M YoY+36.2% | -287M YoY-20.1% | -239M YoY-27.8% | -187M YoY-43.5% | -130M YoY-26.7% | |
-$3.68 YoY+38.6% | -$5.99 YoY-13.7% | -$5.27 YoY-14.6% | -$4.60 YoY-32.6% | -$3.47 YoY-25.3% | ||
| Balance Sheet | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
589M YoY+21.4% | 485M YoY-3.8% | 504M YoY+105.3% | 246M YoY+183.9% | 86.5M YoY-53.0% | ||
690M YoY+21.3% | 568M YoY-3.4% | 588M YoY+77.5% | 331M YoY+277.6% | 87.8M YoY-52.8% | ||
379M YoY+64.6% | 230M YoY+65.7% | 139M YoY+43.8% | 96.6M YoY+318.6% | 23.1M YoY-1.6% | ||
602M YoY+17.6% | 511M YoY+28.8% | 397M YoY+79.0% | 222M YoY+207.6% | 72.2M YoY-0.3% | ||
88.3M YoY+54.9% | 57.0M YoY-70.1% | 191M YoY+74.3% | 110M YoY+600.9% | 15.6M YoY-86.3% | ||
| Cash Flow | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
-93.4M YoY+27.3% | -128M YoY+11.5% | -145M YoY-24.5% | -117M YoY-7.7% | -108M YoY-37.9% | ||
-480K YoY-77.8% | -270K YoY+53.6% | -582K YoY+98.9% | -53.7M YoY-17335.7% | -308K YoY-571.2% | ||
101M YoY+75.4% | 57.8M YoY-82.5% | 331M YoY+16.3% | 285M YoY+2456.9% | 11.1M YoY-73.8% | ||
| Net change in cash | 7.58M YoY+110.7% | -70.8M YoY-138.2% | 185M YoY+62.1% | 114M YoY+217.4% | -97.4M YoY-169.9% | |
| Interest paid | 14.6M YoY-25.7% | 19.7M YoY+17.7% | 16.7M YoY+117.7% | 7.69M YoY+66.2% | 4.63M YoY+120.5% | |
| Income taxes paid | -180K | — | — | — | — | |
| Valuation Ratios | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| Market cap | 9.34B YoY+126.4% | 4.13B YoY+9.6% | 3.77B YoY+12.4% | 3.35B YoY+130.4% | 1.45B YoY-52.3% | |
| P/S | 14.6× YoY+36.8% | 10.7× YoY-36.5% | 16.9× | — | — | |
| P/B | 105.8× YoY+46.2% | 72.4× YoY+417.9% | 14.0× YoY-34.3% | 21.3× YoY-77.1% | 93.0× YoY+247.3% | |
| Source filing | 10-K | 10-K | 10-K | 10-K | 10-K |
About this data
Source: AXSM's SEC filings (10-K / 10-Q). Annual columns are as-reported fiscal years; quarterly columns are as-reported fiscal quarters (Q4 derived as full-year minus the first three quarters where a company doesn't file a standalone Q4); TTM (quarterly) rolls the trailing four quarters at every quarter end, TTM (yearly) samples that one year apart; balance-sheet rows show the period-end balance. Valuation ratios are sampled as of each period end. View all AXSM filings on SEC EDGAR → Not investment advice.
